Fig. 4

MEKi does not increase IRF3 activation nor its translocation into the nucleus. a AlphaLISA analysis of IFN-β in the supernatants of AECs transfected with IRF3 or NT siRNA followed by treatment with DMSO or MEKi and subsequent stimulation with poly(I:C) for 4h. b Immunoblot analysis (with anti-pIRF3, anti-IRF3, α-tubulin, and HDAC2) of fractionated AECs pretreated with DMSO or MEKi for 1h followed by stimulation with or without poly(I:C) for 1-8h. c Native immunoblot analysis (with anti-IRF3) of AECs pretreated with DMSO or MEKi for 1h followed by stimulation with or without poly(I:C) for 1-4h. d Confocal microscopy analysis of IRF3 translocation in AECs pretreated with DMSO or MEKi for 1h followed by stimulation with or without poly(I:C) for 1-8h. e qRT-PCR analysis of HERC5 mRNA in AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). Each symbol () represents a donor and the horizontal bars represent the grand median in a and e (n = 6). b and c are representative immunoblots (n = 6). d is representative of confocal images (n = 6). Statistical analysis was performed with the Wilcoxon signed-rank test. * p < 0.05 indicates statistical significance